Clements D - Search Results

1

Editorial Expression of Concern: The NAD⁺ salvage pathway modulates cancer cell viability via p73.

Sharif T, Ahn DG, Liu RZ, Pringle E, Martell E, Dai C, Nunokawa A, Kwak M, Clements D, Murphy JP, Dean C, Marcato P, McCormick C, Godbout R, Gujar SA, Lee PWK. Sharif T, et al. Among authors: clements d. Cell Death Differ. 2024 Nov;31(11):1577. doi: 10.1038/s41418-024-01382-7. Cell Death Differ. 2024. PMID: 39425001 Free article. No abstract available.

2

The NAD(+) salvage pathway modulates cancer cell viability via p73.

Sharif T, Ahn DG, Liu RZ, Pringle E, Martell E, Dai C, Nunokawa A, Kwak M, Clements D, Murphy JP, Dean C, Marcato P, McCormick C, Godbout R, Gujar SA, Lee PW. Sharif T, et al. Among authors: clements d. Cell Death Differ. 2016 Apr;23(4):669-80. doi: 10.1038/cdd.2015.134. Epub 2015 Nov 20. Cell Death Differ. 2016. PMID: 26586573 Free PMC article.

3

The NAD⁺ Salvage Pathway Supports PHGDH-Driven Serine Biosynthesis.

Murphy JP, Giacomantonio MA, Paulo JA, Everley RA, Kennedy BE, Pathak GP, Clements DR, Kim Y, Dai C, Sharif T, Gygi SP, Gujar S. Murphy JP, et al. Cell Rep. 2018 Aug 28;24(9):2381-2391.e5. doi: 10.1016/j.celrep.2018.07.086. Cell Rep. 2018. PMID: 30157431 Free PMC article.

4

The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Pan LZ, Ahn DG, Sharif T, Clements D, Gujar SA, Lee PW. Pan LZ, et al. Among authors: clements d. Cell Cycle. 2014;13(6):1041-8. doi: 10.4161/cc.28128. Epub 2014 Feb 7. Cell Cycle. 2014. PMID: 24552824 Free PMC article.

5

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses.

Gujar SA, Clements D, Lee PW. Gujar SA, et al. Among authors: clements d. Oncoimmunology. 2014 Jan 1;3(1):e27622. doi: 10.4161/onci.27622. Epub 2014 Jan 6. Oncoimmunology. 2014. PMID: 24804161 Free PMC article.

6

Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.

Clements DR, Sterea AM, Kim Y, Helson E, Dean CA, Nunokawa A, Coyle KM, Sharif T, Marcato P, Gujar SA, Lee PW. Clements DR, et al. J Immunol. 2015 May 1;194(9):4397-412. doi: 10.4049/jimmunol.1402132. Epub 2015 Mar 30. J Immunol. 2015. PMID: 25825443

7

All that glitters is not gold: the need to consider desirable and undesirable immune aspects of oncolytic virus therapy.

Clements DR, Kim Y, Gujar SA, Lee PW. Clements DR, et al. Oncoimmunology. 2015 Jun 5;5(1):e1057674. doi: 10.1080/2162402X.2015.1057674. eCollection 2016. Oncoimmunology. 2015. PMID: 26942069 Free PMC article.

8

Reovirus in cancer therapy: an evidence-based review.

Clements D, Helson E, Gujar SA, Lee PW. Clements D, et al. Oncolytic Virother. 2014 Jul 9;3:69-82. doi: 10.2147/OV.S51321. eCollection 2014. Oncolytic Virother. 2014. PMID: 27512664 Free PMC article. Review.

9

Autophagic homeostasis is required for the pluripotency of cancer stem cells.

Sharif T, Martell E, Dai C, Kennedy BE, Murphy P, Clements DR, Kim Y, Lee PW, Gujar SA. Sharif T, et al. Autophagy. 2017 Feb;13(2):264-284. doi: 10.1080/15548627.2016.1260808. Epub 2016 Dec 8. Autophagy. 2017. PMID: 27929731 Free PMC article.

10

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.

Gujar SA, Clements D, Dielschneider R, Helson E, Marcato P, Lee PW. Gujar SA, et al. Among authors: clements d. Br J Cancer. 2014 Jan 7;110(1):83-93. doi: 10.1038/bjc.2013.695. Epub 2013 Nov 26. Br J Cancer. 2014. PMID: 24281006 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

569 results

Search Page

Filters